By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



3925 West Braker Lane

Austin  Texas  78759  U.S.A.
Phone: 512-961-1891 Fax: 512-305-0009



Company News
Savara Appoints David L. Lowrance As CFO 11/2/2016 9:05:54 AM
Savara Completes Acquisition Of Serendex Pharmaceuticals 7/18/2016 6:38:37 AM
Savara Acquires Serendex Pharmaceuticals 6/21/2016 6:56:51 AM
Savara Completes $20 Million Round Of Financing 3/1/2016 6:31:19 AM
Savara To Present At The 22nd Annual BioCentury Future Leaders In The Biotech Industry Conference 3/16/2015 10:13:47 AM
Savara's AeroVanc Meets Primary Endpoint Of MRSA Reduction In Phase 2 Trial In People With Cystic Fibrosis 2/23/2015 6:43:35 AM
Savara Reels In $10 Million 10/6/2014 6:12:41 AM
Savara Announces FDA Grant of Qualified Infectious Disease Product (QIDP) And Fast Track Designation For Its Lead Product, AeroVanc 12/10/2013 11:25:05 AM
Savara Appoints Two New Members To Its Board of Directors 12/5/2013 6:27:07 AM
Cystic Fibrosis Foundation Therapeutics, Inc. Provides Savara $1.7 Million Award for Development of AeroVanc for MRSA Lung Infection in Cystic Fibrosis Patients 10/17/2013 10:47:30 AM